Tumor dormancy therapy in head and neck cancer
スポンサーリンク
概要
- 論文の詳細を見る
For the purpose of tumor dormancy therapy, UFT+Mitomycin C or TS-1 in patients with recurrent head and neck cancer was studied. Toxicity was not greater in the patients with a higher incidence of grade 2. One patient has survived for more than 4 years, having been given UFT+Mitomycin C at the beginning. For patients with lung metastasis, median survival time was 600 days, and time to progression was 4.5 months in the TS-1 group (n=4). TS-1 method was useful in terms of QOL. Based on these results, we believe that tumor dormancy therapy will be realized for the treatment of recurrent or lung metastastic head and neck cancer.
- 特定非営利活動法人 日本頭頸部外科学会の論文
特定非営利活動法人 日本頭頸部外科学会 | 論文
- 小児・若年者（19歳以下）甲状腺乳頭癌の3症例
- 小児の鼻副鼻腔炎症の取り扱い
- 急性喉頭蓋炎に続発した披裂部膿瘍例
- 軟素材による外耳道再建型鼓室形成術 : ―20年間の経験と本法における外耳道入口部拡大法―
- 当科における遊離移植による頭頸部再建手術の検討